Ring Sideroblasts

Definition
  • ≥5 iron staining granules (+)
  • Encircling at least 1/3 of the nucleus

Diagnostic criteria for significant in MDS are ≥15% ring sideroblasts without evidence (or knowledge) of a SB3F1 mutation.  This threshold drops to ≥5% with a SB3F1 mutation)


Pathobiology
  • Ring sideroblasts represent abnormal accumulation of iron in mitochondria.
  • In neoplastic conditions, is strongly associated with SB3F1 heterozygous mutations (important for RNA splicing).
    • 80-90% of cases of MDS-RS SLD have SB3F1 mutation
    • 30-70% of cases of MDS-RS MLD have SB3F1 mutation
    • ~20% of MDS/MPN cases have SB3F1 mutation
    • ~25% of all cases of MDS have a SB3F1 mutation
    • The present of a SB3F1 mutation is not “specific” for a disease, but there is a 97.7% positive predictive value of finding ring sideroblasts in patients with a SB3F1 mutation.

Association with hematologic disease
  • Multiple hematologic neoplasms may have ringed sideroblasts (following list is not all inclusive)
    • MDS-RS with SLD
    • MDS-RS with MLD
    • MDS with isolated del(5q)
    • Other MDS entities with higher grade features (e.g. MDS-EB, formally RAEB)
    • AML
Non-Neoplastic Etiology of Ring Sideroblasts
  • Hereditary sideroblastic anemias
  • Drug effect (INH, chloramphenicol, cycloserine)
  • Nutritional deficiency (e.g. copper deficiency, which may be secondary to excessive zinc intake)
  • Alcohol
  • Toxin exposure (e.g. zinc, lead or benzene)

Type of Sideroblasts
  • Type 1 – <5 cytoplasmic staining iron granules
  • Type 2  ≥5 cytoplasmic staining iron granules NOT in a perinuclear pattern
  • Type 3 – ≥5 iron staining granules encircling at least 1/3 of the nucleus (ring sideroblast)
Photomircographs
Ring Sideroblasts
Ring Sideroblasts
Ring Sideroblasts
Ring Sideroblasts
Ring Sideroblasts
Ring Sideroblasts
Type 2 sideroblast
Type 2 sideroblast
Sideroblast - Type 2
Sideroblast – Type 2

References
Alcindor T, Bridges KR. Sideroblastic anaemias. Br J Haematol. 2002;116: 733–743.
 
Obeng EA, Chappell RJ, Seiler M, Chen MC, Campagna DR, Schmidt PJ, et al. Physiologic Expression of Sf3b1(K700E) Causes Impaired Erythropoiesis, Aberrant Splicing, and Sensitivity to Therapeutic Spliceosome Modulation. Cancer Cell. 2016;30: 404–417. doi:10.1016/j.ccell.2016.08.006
 
Malcovati L, Karimi M, Papaemmanuil E, Ambaglio I, Jädersten M, Jansson M, et al. SF3B1 mutation identifies a distinct subset of myelodysplastic syndrome with ring sideroblasts. Blood. 2015;126: 233–241. doi:10.1182/blood-2015-03-633537
 
Swerdlow SH, Campo E, Harris, NL, Jaffe ES, Pileri SA, Stein H, Thiele J (Eds):  WHO Classification of Tumours of Haematopoietic and Lymphoid Tissues (Revised 4th edition). IARC: Lyon 2017